A PHASE 2/3 RANDOMIZED, MULTICENTER STUDY OF OSIVELOTOR ADMINISTERED ORALLY TO ADULT AND ADOLESCENT PARTICIPANTS WITH SICKLE CELL DISEASE
- Registry ID
- C5351004 (GBT021601-021)
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- GLOBAL BLOOD THERAPEUTICS INC
- Last update
- 2025-12-09
Conditions
- SICKLE CELL DISEASE
- SICKLE CELL ANEMIA
Related clinical trials
- A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER,
DOSE-FINDING, EFFICACY, AND SAFETY STUDY OF TEBAPIVAT IN PARTICIPANTS WITH
SICKLE CELL DISEASE
- OPTIMA STUDY : OPTIMIZING HYDROXYUREA DOSAGE WITH PHARMAKOKINETIC IN PATIENTS SUFFERING OF MODERATE TO SEVERE SICKLE CELL ANEMIA.
- A PHASE 2A, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE MULTIPLE DOSING REGIMENS OF SUBCUTANEOUS ALXN1820 IN ADULT PATIENTS WITH SICKLE CELL DISEASE
- EARLY HLA MATCHED SIBLING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE: A SICKLE TRANSPLANT ALLIANCE FOR RESEARCH (STAR) TRIAL
- A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MITAPIVAT IN SUBJECTS WITH SICKLE CELL DISEASE
- THROMBOPROPHYLAXIS IN SICKLE CELL DISEASE WITH CENTRAL VENOUS CATHETERS (THIS): A PILOT STUDY
View on source registry